TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26311707
Drug: Powder mastic
Normalized name: Thymus mastichina flowering top oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder mastic (PM, n=28) receiving daily a total dose of 2 g of crude CMG
Study: 18595435
Drug: eszopiclone 1
Normalized name: eszopiclone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eszopiclone 1 mg
Study: 18595435
Drug: eszopiclone 2
Normalized name: eszopiclone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eszopiclone 2 mg
Study: 18595435
Drug: eszopiclone 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: eszopiclone 2.5 mg
Study: 18595435
Drug: eszopiclone 3
Normalized name: eszopiclone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eszopiclone 3 mg
Study: 18595435
Drug: zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: zolpidem 10 mg
Study: 9390614
Drug: I.V. fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. fentanyl 2 microg/kg, followed by an infusion at the rate of 25 ng x kg(‐1) x min(‐1)
Study: 9390614
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl injection and infusion at the same administration regimen as Group II
Study: 9390614
Drug: Bolus injections
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injections of both epidural and intravenous saline, followed by both epidural and I.V. infusions at the rate of 0.2 mL x kg(‐1) h(‐1)
Study: 3116847
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy after conservative breast surgery plus irradiation
Study: 21910335
Drug: Thermotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermotherapy combined with thoracic injection of lentinan
Study: 16469112
Drug: lumiracoxib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: lumiracoxib 400 mg/day (n = 144)
Study: 16469112
Drug: celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib 200 mg twice daily (n = 145)
Study: 12846090
Drug: Combined conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined conservative treatment (antibacterial therapy, transcutaneous laser irradiation of the suprapubic region using intravesical methods)
Study: 12846090
Drug: Combined conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined conservative treatment plus transurethral resection (TUR) of the urinary bladder mucosa
Study: 29051989
Drug: Iguratimod 3.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iguratimod 3.125 to 50 mg
Study: 29051989
Drug: Iguratimod 25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iguratimod 25, 50, 75 mg
Study: 29051989
Drug: Iguratimod 50
Normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Iguratimod 50 mg (multiple doses)
Study: 29051989
Drug: Iguratimod 50
Normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Iguratimod 50 mg (single dose)
Study: 29051989
Drug: Iguratimod 50
Normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Iguratimod 50 mg (fed group)
Study: 29051989
Drug: Iguratimod 50
Normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Iguratimod 50 mg (fasted group)
Study: 27077129
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of autologous adipose-derived regenerative cells (ADRCs)
Study: 27077129
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of ADRCs in continent men
Study: 27077129
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection of ADRCs in incontinent men
Study: 18303965
Drug: Iloperidone 24
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloperidone 24 mg/day
Study: 10689152
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated VZV vaccine (Oka 3200)
Study: 10689152
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated VZV vaccine (Oka 8500)
Study: 10689152
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated VZV vaccine (Oka 41650)
Study: 10689152
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Pneumo 23 vaccine)
Study: 10689152
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated VZV vaccine (all groups)
Study: 10689152
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated VZV vaccine
Study: 1286054
Drug: Conventional intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intramuscular meperidine
Study: 31392213
Drug: Faroese chain
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faroese chain dance intervention (twice‐weekly sessions for 6 weeks, 30 min for first 3 weeks, 45 min for last 3 weeks)
Study: 26333044
Drug: Secondary prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary prevention using 800 mcg sublingual misoprostol administered to women with postpartum blood loss ≥350 ml
Study: 26333044
Drug: Universal prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal prophylaxis using 600 mcg oral misoprostol administered to all women during the third stage of labour
Study: 16638037
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and clomiphene citrate
Study: 10329808
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray 0.14 mg per nostril twice daily
Study: 10329808
Drug: Cetirizine tablets
Normalized name: cetirizine Oral Tablet
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine tablets 10 mg every day
Study: 8534682
Drug: Peritoneal equilibration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal equilibration test (PET) performed twice
Study: 1938800
Drug: Thioridazine (1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (1.75 mg/kg/day)
Study: 29241909
Drug: Hyoscine butyl-bromide
Normalized name: Butyl Alcohol
DrugBank: Butyl alcohol (DB02145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butyl-bromide (20 mg in 1 ml)
Study: 27076940
Drug: S-1 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 with concurrent radiotherapy
Study: 18089875
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (gemcitabine/platinum without cetuximab)
Study: 10464830
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol 0.2 mg four times daily
Study: 8392897
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 4 mg four times daily
Study: 7589374
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 50 micrograms b.i.d.
Study: 7589374
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 400 micrograms b.i.d.
Study: 6268269
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy and irradiation
Study: 6268269
Drug: Delayed chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed chemotherapy following radiotherapy recurrence
Study: 6268269
Drug: Chemotherapy groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy groups
Study: 6268269
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of irradiation
Study: 31449577
Drug: Platform-switched implant
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switched implant
Study: 31449577
Drug: Platform-matched implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-matched implant
Study: 23721147
Drug: Intensity-modulated radiotherapy
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity-modulated radiotherapy (IMRT) with simultaneous-integrated boost and weekly cisplatin 40 mg/m² (median 6 cycles)
Study: 21855223
Drug: Acute nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute nicotine administration (placebo, low, or high dose nicotine patch)
Study: 21855223
Drug: Non-smoking controls
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-smoking controls (placebo or low dose)
Study: 21855223
Drug: Acute nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute nicotine administration
Study: 19151048
Drug: Levosimendan (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (24 microg kg(‐1) administered as a slow i.v. bolus over 10 min)
Study: 10841002
Drug: Insulin glargine[15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin glargine[15]
Study: 10841002
Drug: Insulin glargine[80]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin glargine[80]
Study: 10841002
Drug: Insulin glargine[30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin glargine[30]
Study: 10174312
Drug: Tiludronic acid
Normalized name: tiludronic acid
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiludronic acid (400 mg/day)
Study: 6584449
Drug: Calcium (1
Normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1 g) daily for 180 days
Study: 6584449
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets daily for 180 days
Study: 12891225
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg aprepitant on day 1 and then 80 mg/d on days 2 to 5
Study: 12891225
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg aprepitant on day 1 and then 25 mg/d on days 2 to 5
Study: 525982
Drug: Levamisole (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (three different doses)
Study: 28086848
Drug: Parents as
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents as Agents of Change (PAC©) intervention, a manualized, 16-session, group-based, health care professional-led intervention for parents
Study: 25120110
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) supplementation (980 mg polyphenols daily)
Study: 16827252
Drug: Buprenorphine 30
Normalized name: BUPRENORPHINE 300MCG BUCCAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 30 micrograms with hyperbaric bupivacaine 0.75% 2 ml (group B)
Study: 16827252
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 micrograms with hyperbaric bupivacaine 0.75% 2 ml (group F)
Study: 16827252
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 0.75% 2 ml (group L control)
Study: 12811695
Drug: CT-guided intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided intra-articular corticosteroid injection (low-dose injection)
Study: 12811695
Drug: NSAIDs therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs therapy
Study: 7762835
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 micrograms and propofol 35 mg (FP)
Study: 7762835
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 micrograms and midazolam 2 mg (FM)
Study: 7762835
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 micrograms, midazolam 2 mg, and propofol 35 mg (FMP)
Study: 7762835
Drug: Alcohol 56
Normalized name: ALCOHOL 56 mg in 1 g TOPICAL SPRAY [CVS Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 56 g (orally administered)
Study: 2113967
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg DOPS
Study: 2113967
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg DOPS
Study: 105656
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin regimen (0.44 U/kg body weight loading dose half intramuscularly and half intravenously followed by 7 U/h intramuscularly)
Study: 105656
Drug: Constant infusion
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant infusion of 7 U/h in albumin-free saline (0.44 U/kg loading dose intravenously)
Study: 26880570
Drug: DAPT interruption
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT interruption (aspirin only)
Study: 21223673
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture therapy (AAT) on active points
Study: 16415999
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 5 mg
Study: 16415999
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 20 mg
Study: 16415999
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 40 mg
Study: 16415999
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 60 mg
Study: 7538555
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 5 micrograms/kg/d beginning on day + 1 following transplant
Study: 7538555
Drug: G-CSF in
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF in patients who received PBSC alone
Study: 7538555
Drug: G-CSF in
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF in patients who received PBSC with bone marrow
Study: 2157240
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose proton treatment
Study: 27977473
Drug: Bremelanotide 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bremelanotide 1.25 mg
Study: 10873400
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy using radiation alone
Study: 8249563
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of morphine in saline
Study: 2411072
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 10% zinc sulfate in Aquaphor ointment
Study: 18612188
Drug: Fluvastatin, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin, 80 mg/day, orally for 6 weeks
Study: 16037178
Drug: RM group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RM group (0.25% ropivacaine and morphine 0.2 mg/mL)
Study: 16037178
Drug: RMK group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMK group (0.25% ropivacaine, morphine 0.2 mg/mL and ketorolac 1 mg/mL)
Study: 11922560
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg once daily (n = 93)
Study: 11922560
Drug: Mesalazine 2
Normalized name: mesalazine 2 GM per 59 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 2 g b.i.d. (n = 89)
Study: 11922560
Drug: Mesalazine 2
Normalized name: mesalazine 2 GM per 59 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 2 g b.i.d.
Study: 8780276
Drug: Intravenous buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous buprenorphine 2 micrograms/kg
Study: 8780276
Drug: Intravenous buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous buprenorphine 4 micrograms/kg
Study: 1632979
Drug: Natural leukocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural leukocyte alpha interferon (IFN) administered at 6 MU i.m. daily for 4 weeks and thereafter 3 times per week for 2 months, combined with radiotherapy (2 Gy daily, 5 fractions per week)
Study: 6708391
Drug: Digoxin administration
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin administration (plasma levels 1.55 +/‐ 0.27 ng/ml) lasting 35 days
Study: 6708391
Drug: Digoxin administration
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin administration with maximal stimulation of adrenal and gonadal glands by ACTH and hCG
Study: 6708391
Drug: Digoxin administration
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin administration over a period of 150‐210 days
Study: 26363127
Drug: Demands and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demands and Capacities-based treatment
Study: 26363127
Drug: Lidcombe Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidcombe Program and Demands and Capacities-based treatment
Study: 9640080
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ZPP measurement with ferritin and peripheral blood morphology
Study: 8102829
Drug: Vecuronium doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium doses ranging from 0.1 to 0.3 mg kg‐1
Study: 3813189
Drug: Urapidil (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (0.75 mg/kg)
Study: 3813189
Drug: Hydralazine (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (0.35 mg/kg)
Study: 28750894
Drug: Capsule and
Normalized name: COMBINATION PACKAGE, CAPSULE AND PAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule and disc shaped printlets
Study: 23041092
Drug: vWF >
Approvals — FDA: no, EMA: no, PMDA: no
Description: vWF > 1434.92 mU/ml
Study: 15106359
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (calcium 1000 mg/day)
Study: 11334476
Drug: EE35/CPA (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE35/CPA (2.0 mg cyproterone acetate and 35 microg ethinylestradiol for 21 days)
Study: 9127977
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity intervention (twice-weekly sessions of low intensity movements for one year)
Study: 26340656
Drug: Light-touch sham
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-touch sham treatment
Study: 25258523
Drug: IG/HD +
Approvals — FDA: no, EMA: no, PMDA: no
Description: IG/HD + RCH (210 g of ricotta cheese daily)
Study: 22682721
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally 24 hours prior to abortion
Study: 15753242
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) combined with pharmacotherapy
Study: 11388815
Drug: Home service
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home service (automatic transmission of blood pressure data, computerized report forms, weekly electronic transmission)
Study: 3326920
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus Nifedipine (50 mg and 20 mg twice daily respectively)
Study: 19214122
Drug: 3% SPL7013
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% SPL7013 gel (n = 24)
Study: 19214122
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (n = 12)
Study: 19214122
Drug: SPL7013 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPL7013 gel
Study: 17237130
Drug: Carvedilol (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (n = 1511, target dose 50 mg daily)
Study: 17237130
Drug: Metoprolol (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (n = 1518, target dose 100 mg daily)
Study: 11352444
Drug: Theophylline 400mg
Normalized name: THEOPHYLLINE 400MG TAB,SA
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline 400mg alone (Treatment B)
Study: 11352444
Drug: Theophylline 400mg
Normalized name: THEOPHYLLINE 400MG TAB,SA
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline 400mg plus moxifloxacin 200mg (Treatment C)
Study: 11352444
Drug: Moxifloxacin 200mg
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin 200mg alone (Treatment A)
Study: 9797810
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDCT) with autologous stem cell rescue
Study: 9797810
Drug: HDCT in
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDCT in first-line therapy for poor-risk GCTs
Study: 28870554
Drug: Conventional professional
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional professional based speech language therapy (SLT) alone (Group A/less intensive)